$AZN News
Last published 1d ago
- 1d agoAZNAstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the USBusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community Solu ...
- 2d agoLEGNGILDAZNMCK+4Gabelli Releases Agenda for 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
- 5d agoAAPLNVDAIBMJNJ+4U.S. Reshoring and Nearshoring: A Sustainable Economic TailwindStifel InsightsMarket Sight | Lines Investors are increasingly worried about market levels and the possibility of an artificial intelligence (AI) “bubble.” Despite the worries, however, during earnings calls and elsewhere, executives are highlighting a powerful, long-term positive theme: making more in America. What began as a reaction to pandemic-era disruptions has evolved into a structural reindustrializatio ...
- 1w agoTYO:4568AZNEnhertu® Wins 2026 International Prix Galien Award for Best Biotechnology ProductBusiness WireSecond Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024 Enhertu® (trastuzumab deruxtecan) has been awarded the 2026 International Prix Galien
- 1w agoAZNAstraZeneca results: 9M and Q3 2026Business WireContinued strong commercial performance and 12 positive Phase III programme readouts in the year to date AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 %
- 1w agoGENBBMYNTHIAZN2027 Could Finally Be the Year Cancer Is on the Ropes!GlobeNewswireDENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
- 2w agoAZNAstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker TestingBusiness WireCampaign encourages people to take a "time out" to learn more about cancer biomarker testing, which can guide more personalized cancer treatment decisions AstraZeneca today announced the launch of Meet Your
- 2w agoTYO:4568AZNEnhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerBusiness WireApproval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of
- 2w agoLLYNVOAZNRHHBYBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of
- 2w agoLEGNGILDAZNMCK+5Gabelli To Host 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
- 2w agoAZNSonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01Business WireSone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this
- 2w agoAZNTAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOBusiness WireTAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing
- 2w agoAZNIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialBusiness WireNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy
- 2w agoAMGNAZNAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancerCNBCA drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
- 2w agoAZNPerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerBusiness WireMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically
- 2w agoAZNApproval of Symbicort Aerosphere, Nda #216579 (Labeling)FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Symbicort Aerosphere, Nda #216579; Active Ingredients: BUDESONIDE; FORMOTEROL FUMARATE; Company: Astrazeneca; Submission Status: Approval; Submission Classification: Labeling; Application Number: 216579
- 2w agoAZNZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsBusiness WireOnly approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of
- 3w agoAZNTEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology WeekBusiness WireFirst and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placebo TEZSPIRE
- 3w agoAZNAstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinibBusiness WireCLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients SAFFRON results will highlight clinical benefit of adding
- 1mo agoSOPHMYGNAZNSOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPR NewswireBOSTON, Oct. 8, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ:MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to
- 1mo agoGILDSMMTAZNMRKAstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investmentCNBCPascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
- 1mo agoAZNAstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, MassachusettsBusiness Wire$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicines AstraZeneca today announced the opening of its newest global strategic research and
- 1mo agoSMMTAZNAstraZeneca Completes $2 Billion Equity Investment in Summit TherapeuticsBusiness WireSummit Therapeutics Inc. (NASDAQ:SMMT) today announced the successful closing of AstraZeneca’s (NYSE:AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the
- 1mo agoSMMTAZNSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayBusiness WireCollaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer Summit Therapeutics Inc.
- 1mo agoTSX:4568AZNSMMTDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesBusiness WireDaiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE:AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (NASDAQ:SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination
- 1mo agoSMMTAZNAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsBusiness WireInvestment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into
- 1mo agoAZNPerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancerBusiness WireBased on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival AstraZeneca’s supplemental Biologics License
- 1mo agoAZNApproval of Crestor, Nda #021366 (Labeling)FDA Approved DrugsApproval Date: 09/23/2026; Drug Name: Crestor, Nda #021366; Active Ingredients: ROSUVASTATIN CALCIUM; Company: Astrazeneca; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021366
- 1mo agoTYO:4568AZNEnhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerBusiness WireRecommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the
- 1mo agoAZNApproval of Truqap, Nda #218197 (Efficacy)FDA Approved DrugsApproval Date: 09/16/2026; Drug Name: Truqap, Nda #218197; Active Ingredients: CAPIVASERTIB; Company: Astrazeneca; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218197
- 1mo agoAZNApproval of Tagrisso, Nda #208065 (Efficacy)FDA Approved DrugsApproval Date: 09/14/2026; Drug Name: Tagrisso, Nda #208065; Active Ingredients: OSIMERTINIB MESYLATE; Company: Astrazeneca; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 208065
- 1mo agoAZNApproval of Tagrisso, Nda #208065 (Labeling)FDA Approved DrugsApproval Date: 09/14/2026; Drug Name: Tagrisso, Nda #208065; Active Ingredients: OSIMERTINIB MESYLATE; Company: Astrazeneca; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208065
- 1mo agoAZNENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trialBusiness Wire6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of
- 1mo agoAZNTAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trialBusiness WireLongest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages Updated exploratory
- 1mo agoTYO:4568AZNEnhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialBusiness WireRepresents a six-month improvement in median progression-free survival versus pembrolizumab plus chemotherapy Daiichi Sankyo and AstraZeneca’s Enhertu is the first HER2 directed medicine to delay disease
- 2mo agoAZNIMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancerBusiness WireIMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy
- 2mo agoAZNTozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trialsBusiness WireTozorakimab showed clinically meaningful benefits across blood eosinophil thresholds Full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress
- 2mo agoAZNREGNSNYGSKAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopesCNBCThe full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
- 2mo agoAZNETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancerBusiness WireApproval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation Innovative treatment strategy has
- 2mo agoAZNFDA Grants Accelerated Approval to a New Breast Cancer TreatmentFDA Press ReleasesThe U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adu ...
- 2mo agoAZNAstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancerBusiness WireAstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth
- 2mo agoTYO:4568AZNEnhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast CancerBusiness WireApproval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median
- 2mo agoAZNTEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpointsBusiness WireStatistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad potential
- 2mo agoSBFMBNTXAZNMRNA+1A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityGlobeNewswireNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is
- 2mo agoTYO:4568AZNTROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial CancerBusiness WireThe first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab
- 2mo agoHYFTABCLABSILLY+1Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.GlobeNewswireNEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it
- 2mo ago005930.KSKSIE.DESPOT+6Stifel BitsStifel Insights76.9°F: The average temperature in July for the contiguous U.S., breaking the record for the hottest month on record, previously set in July 1936.406.320 mph: The speed achieved by British driver Andy Green in a car powered by two hydrogen internal combustion engines, setting the land-speed record for that vehicle category.
- 2mo agoAZNENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trialBusiness WireAstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of care in a Phase III trial in this setting Positive high-level results
- 2mo agoAZNTAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOBusiness WireFirst global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer Positive
- 2mo agoTYO:4568AZNEnhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialBusiness WireDaiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting Data to be presented at an